Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials

被引：0
|
作者：
Strain, W. D. [1 ]
Holst, A. G. [2 ]
Rasmussen, S. [2 ]
Saevereid, H. A. [2 ]
James, M. A. [1 ]
机构：
[1] Univ Exeter, Med Sch, Exeter, Devon, England
[2] Novo Nordisk AS, Soborg, Denmark
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2424 / 2424
页数：1
相关论文
共 50 条
  • [1] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S130 - S131
  • [2] Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
    Strain, W. David
    Frenkel, Ofir
    James, Martin A.
    Leiter, Lawrence A.
    Rasmussen, Soren
    Rothwell, Peter M.
    Ripa, Maria Sejersten
    Truelsen, Thomas C.
    Husain, Mansoor
    [J]. STROKE, 2022, 53 (09) : 2749 - 2757
  • [3] Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
    Verma, Subodh
    Bain, Stephen C.
    Fries, Tea Monk
    Mazer, C. David
    Nauck, Michael A.
    Pratley, Richard E.
    Rasmussen, Soren
    Saevereid, Hans A.
    Zinman, Bernard
    Buse, John B.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1745 - 1751
  • [4] DURATION OF DIABETES AND CARDIORENAL EFFICACY OF LIRAGLUTIDE AND SEMAGLUTIDE: A POST HOC ANALYSIS OF THE LEADER AND SUSTAIN-6 CLINICAL TRIALS
    Verma, Subodh
    Bain, Stephen C.
    Honore, Julie Broe
    Fries, Tea Monk
    Nauck, Michael A.
    Pratley, Richard E.
    Rasmussen, Soren
    Zinman, Bernard
    Buse, John
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1704 - 1704
  • [5] Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials
    Verma, Subodh
    Leiter, Lawrence A.
    Michelsen, Marie M.
    Orsted, David
    Rasmussen, Soren
    Bhatt, Deepak L.
    [J]. CIRCULATION, 2020, 142
  • [6] EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS
    Tuttle, Katherine
    Cherney, David
    Hadjadj, Samy
    Idorn, Thomas
    Mosenzon, Ofri
    Perkovic, Vlado
    Rasmussen, Soren
    Wolthers, Benjamin
    Bain, Stephen C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 152 - 152
  • [7] Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Petrie, Mark
    Bain, Stephen
    Hoff, Soren Tetens
    Johansen, Nicklas
    Rasmussen, Soren
    Vilsboell, Tina
    Husain, Mansoor
    [J]. CIRCULATION, 2021, 144
  • [8] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials
    Verma, Subodh
    David, Jens-Peter
    Leiter, Lawrence A.
    Michelsen, Marie Mide
    Rasmussen, Soren
    Bhatt, Deepak L.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
  • [9] Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
    Nauck, Michael A.
    Quast, Daniel R.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [10] Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
    Verma, S.
    Bain, S. C.
    Bhatt, D. L.
    Leiter, L. A.
    Mazer, C. D.
    McGuire, D. K.
    Pratley, R.
    Zinman, B.
    Lindberg, S.
    Rasmussen, S.
    Vrazic, H.
    Buse, J. B.
    [J]. DIABETOLOGIA, 2019, 62 : S560 - S560
12345